MENLO PARK, Calif., May 7, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning algorithms can predict which patients are more likely to experience side effects, specifically nausea, from GLP-1 therapies
I mean, I think when, a couple things, when youve got my trainer whos my age saying, You need to read about this menopause, and you know, Mary Havers really doing some good work over there and shes down the street, and then youve got Peter Attia, whos kind of a bros bro, saying that what weve done to women is the biggest medical ball drop in the last 100 years
Some patients benefit from alternating cycles
What's inside every guide
When a pharmacys entire identity is compounding, quality is not a department it is the institution